M. John Chapman

Lipoprotein(a) as a cardiovascular risk factor: current status

Børge G. Nordestgaard, M. John Chapman, Kausik K. Ray et al. · European Heart Journal · 2010 · 1.8K citations · Full text

Medicine, Cardiology, Clinical Cardiology +16

Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel

Jan Borén, M. John Chapman, Ronald M. Krauss et al. · European Heart Journal · 2020 · 1.5K citations

Medicine, Cardiology, Cardiovascular Genetics +10

Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society

Éric Bruckert, Robert A. Hegele, Jan Albert Kuivenhoven et al. · European Heart Journal · 2014 · 1.1K citations · Full text

Medicine, Cardiology, Genetics +17

Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society

Henry N. Ginsberg, Chris J. Packard, M. John Chapman et al. · European Heart Journal · 2021 · 899 citations · Full text

Life Sciences, Biochemistry, Cardiology +17

Variation in<i>PCSK9</i>and<i>HMGCR</i>and Risk of Cardiovascular Disease and Diabetes

Brian A. Ference, Jennifer G. Robinson, Robert D. Brook et al. · New England Journal of Medicine · 2016 · 784 citations · Full text

Veterinary Medicine, Genetics, Pharmacology +14